Regulus Therapeutics Inc. (NASDAQ:RGLS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02

On May24, 2017, Regulus Therapeutics Inc. (the Company) entered
into an amended and restated employment agreement (the Agreement)
with Daniel R. Chevallard, the Companys Chief Financial Officer.
to the Agreement, Mr.Chevallard is entitled to receive an annual
base salary of $300,000 and is eligible to receive an annual
performance bonus, with a target bonus amount of 40% of his
annual base salary. Mr.Chevallards base salary and target bonus
are subject to periodic review and adjustment from time to time
in the discretion of the Board of Directors of the Company (the
Board) or the Compensation Committee of the Board.

If the Company terminates Mr.Chevallards employment without cause
(other than due to his death or complete disability) or if
Mr.Chevallard resigns for good reason at any time other than
during the period beginning one month before and ending 12 months
following a change in control of the Company, the Company is
obligated to provide to Mr.Chevallard, subject to receiving an
effective release and waiver of claims from him, (1)a lump sum
severance payment equal to 12 months of his base salary in effect
at the time of such termination or resignation (disregarding any
decrease that forms the basis for a resignation for good reason),
(2) a lump sum cash amount equal to 229.56% multiplied by the
total cost of the projected premiums for group medical, dental
and vision insurance for a period of 12 months and (3)vesting
acceleration of all outstanding options and other equity
incentive awards subject to time-based vesting held by
Mr.Chevallard as of such termination or resignation.

If the Company terminates Mr.Chevallards employment without cause
(other than due to his death or complete disability) or if
Mr.Chevallard resigns for good reason, in each case during the
period beginning one month before and ending 12 months following
a change in control of the Company, in addition to the severance
payment described above, the Company is also obligated to pay
Mr.Chevallard, subject to receiving an effective release and
waiver of claims from him, a lump sum payment equal to the target
amount of Mr.Chevallards annual performance bonus for the year of
termination or resignation.

The foregoing is only a summary of the material terms of the
Agreement, and does not purport to be complete and is qualified
in its entirety by reference to the full text of the Agreement, a
copy of which is attached to this report as Exhibit 99.1.

About Regulus Therapeutics Inc. (NASDAQ:RGLS)

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Recent Trading Information

Regulus Therapeutics Inc. (NASDAQ:RGLS) closed its last trading session up +0.02 at 1.38 with 2,107,994 shares trading hands.